Overview

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Status:
Active, not recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) patients.

Phase:

Phase 3

Details

Lead Sponsor:

TG Therapeutics, Inc.

Treatments:

Antibodies, Monoclonal
Chlorambucil
Obinutuzumab